Latest Regulatory Approvals News

Tamboran Resources has appointed Todd Abbott as CEO and made significant progress in drilling and infrastructure development in the Beetaloo Basin, aiming for first gas sales in the third quarter of 2026.

Vita Resources NL has secured regulatory approval to launch its first-ever exploration drilling campaign at the promising Ninnis Gold Project in Western Australia’s Northern Goldfields.

Meteoric Resources has successfully commissioned its Mixed Rare Earth Carbonate pilot plant in Brazil, achieving strong recovery rates and production outputs that validate its processing approach and de-risk the Caldeira project.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

Tivan Limited’s maiden drilling at the Sandover Fluorite Project has delivered ultra high-grade fluorite assays, confirming a robust mineralised system with promising metallurgical qualities. The company is gearing up for a significant follow-up drilling campaign to expand resource definition.

Grand Gulf Energy’s initial fieldwork at its Dry Wash Antimony Project in Utah reveals visible stibnite mineralisation, hinting at promising shallow deposits linked to nearby known mineral systems.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.

Elanor Investors Group has secured securityholder approval for a $125 million recapitalisation with Rockworth Capital Partners and the acquisition of Firmus Capital, marking a pivotal step in stabilising its balance sheet and positioning for growth.

Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.

Godolphin Resources has identified a significant new induced polarisation anomaly 1,000 metres from its Lewis Ponds deposit, alongside high-grade gold, zinc, and copper surface samples, setting the stage for a targeted drilling campaign in March 2026.

NexGen Energy is advancing through the final Canadian Nuclear Safety Commission hearing for its Rook I uranium project, buoyed by strong Indigenous community support and over a decade of environmental and social groundwork.